In neurons, enhanced protein kinase A (PKA) signaling elevates synaptic plasticity, promotes neuronal development, and increases dopamine synthesis. By contrast, a decline in PKA signaling contributes to the etiology of several brain degenerative diseases, including Alzheimer's disease and Parkinson's disease, suggesting that PKA predominantly plays a neuroprotective role. A-kinase anchoring proteins (AKAPs) are large multidomain scaffold proteins that target PKA and other signaling molecules to distinct subcellular sites to strategically localize PKA signaling at dendrites, dendritic spines, cytosol, and axons. PKA can be recruited to the outer mitochondrial membrane by associating with three different AKAPs to regulate mitochondrial dynamics, structure, mitochondrial respiration, trafficking, dendrite morphology, and neuronal survival. In this review, we survey the myriad of essential neuronal functions modulated by PKA but place a special emphasis on mitochondrially localized PKA. Finally, we offer an updated overview of how loss of PKA signaling contributes to the etiology of several brain degenerative diseases.
Introduction
Protein kinase A (PKA) is a master regulator of most cyclic AMP (cAMP)-dependent physiological processes in eukaryotic cells. PKA is a tetrameric holoenzyme composed of two regulatory (R) subunits (classified as type I or type II R subunits) bound to two catalytic (C) subunits. The association of cAMP to a specific site in the molecular surface of the PKA holoenzyme (interface between R and C subunits) leads to the destabilization of the R subunits and induces the release of the C subunits. Depending on the subcellular localization of PKA, the liberated C subunits phosphorylate downstream substrates to regulate critical physiological functions in eukaryotic cells (Feliciello et al., 2001) .
PKA can be targeted to the outer mitochondrial membrane (OMM) via three different A-kinase anchoring proteins (AKAPs), large multidomain PKA anchoring proteins. Mitochondrial AKAPs contain small unique positively charged mitochondrial leader sequences that bind the lipid membrane of mitochondria. A fourth AKAP, termed sphingosine kinase interacting protein, targets PKA to the inner mitochondrial membrane to phosphorylate the coiled-coil helix protein ChChd3 (Means et al., 2011) . At the OMM, protein kinase A (PKA) has emerged as an essential regulator of different aspects of mitochondrial biology, including mitochondrial morphology, dynamics, and turnover, by phosphorylating the OMM-localized dynamin-related protein 1 (Drp1) to inhibit mitochondrial fission, the proapoptotic protein Bcl-2 associated death promoter (BAD) to promote survival, and mitochondrialanchored cytoskeletal proteins to remodel dendrites (Cardone et al., 2002; Affaitati et al., 2003; Merrill et al., 2011) . At the matrix, PKA has been shown to phosphorylate a subunit of complex I (NDUFS4) in vitro and in vivo to elevate oxidative phosphorylation (Papa, 2002) .
The OMM has emerged as a crucial platform by which a myriad of protein signaling pathways converge to regulate essential neuronal functions. The reversible phosphorylation of OMM-localized protein substrates by serine/ threonine (ser/thr) kinases and phosphatases is a crucial posttranslational event that governs mitochondrial structure, metabolism, and mitochondrial oxidative phosphorylation (Pagliarini and Dixon, 2006) .
Mitochondria are multifaceted organelles that not only serve as the main energy hubs to power most eukaryotic physiological reactions but also act as calcium sinks and heat generators and regulate lipid/steroid metabolism and cell survival. Unlike proliferating cells, neurons predominantly rely on oxidative phosphorylation to power essential neuronal functions and survival. The high reliance of neurons on oxidative phosphorylation is evident as mitochondrial dysfunction underlies the etiology of several neurodegenerative disorders, including Parkinson's disease (PD) (Gusdon and Chu, 2010) . In addition to powering the soma, mitochondria are critical for the maintenance of complex and vast neurite networks. Indeed, to achieve this tall order, mitochondria have the challenging task of providing the necessary energy and calcium buffering capacity for the maintenance of dendrites and axons of long projecting neurons. Hence, a continuous turnover of effete mitochondria and a highly coordinated trafficking of de novo mitochondria toward sites of highest energy demands within dendritic arbors and axons are necessary to prevent premature loss of neurites (Cherra et al., 2010; Schwarz, 2013) .
In this review, we purvey the critical role that PKA plays on the maintenance of dendritic arbors, mitochondrial trafficking, mitochondrial function, and survival. Then we discuss how the dysregulation of the activity and the localization of specific pools of PKA contribute to the molecular pathogenesis of various brain degenerative disorders, including Alzheimer's disease (AD) and PD (Andorfer and Davies, 2000; Howells et al., 2000; Yamamoto et al., 2000; Vitolo et al., 2002; Pugazhenthi et al., 2011) , and offer insight as to how ameliorating alterations in PKA signaling may reverse molecular pathogenesis in these diseases.
Role of PKA/AKAP in regulating mitochondrial function and dynamics in neurons
AKAPs, large multimodular protein scaffolds that bind to PKA holoenzymes, have emerged as critical regulators of neuronal development, survival, and metabolism. AKAPs have the ability to relocate endogenous PKA -and other associated signaling players -to distinct subcellular compartments to strategically enhance cAMP-regulated signaling pathways (Feliciello et al., 2001) . For instance, D-AKAP79 is localized at postsynaptic sites to regulate dendritic spine development, morphology, and synaptic plasticity (Gomez et al., 2002) . In addition, D-AKAP150, also known as AKAP79 (human ortholog), targets PKA to dendrites to regulate the activity of acid-sensing ion channels in rat cortical neurons (Chai et al., 2007) . At the OMM, up to three AKAPs have been identified to interact with PKA, including the dual-specificity A-kinase anchoring protein 1 (D-AKAP1), D-AKAP2, and rab32. D-AKAP1 (also known as AKAP140/149 and other splice variants AKAP121 and sAKAP84) is a dual specificity multidomain mitochondrial protein scaffold that not only associates with endogenous PKA but also recruits a host of other signaling molecules to the OMM, including protein kinase C (PKC), src tyrosine kinase, protein phosphatase 2A (PP2A), protein tyrosine phosphatase D1 (Feliciello et al., 2001; Cardone et al., 2004; Carnegie et al., 2009) , and various mRNA molecules . On the basis of Northern blot data alone, D-AKAP1 is widely expressed with high expression levels in the heart and testes, whereas low protein levels have been observed in skeletal muscle and brain tissue (Huang et al., 1997) .
Splice variants of D-AKAP1 contain short divergent N-terminal and C-terminal regions that are spliced to a common core region that contains KH and Tudor domains. To date, six splice variants of D-AKAP1 have been identified (Feliciello et al., 2001) . Although numerous studies suggest that D-AKAP1 plays a critical role in sperm maturation and oocyte development (Carnegie et al., 2009) , the biological in vivo significance of various D-AKAP1 splice variants in neurons is however not clear, given that very low levels of expression have been detected in the brain (Huang et al., 1997) . In vivo, knocking out endogenous D-AKAP1 is not embryonically lethal, suggesting that other mitochondrial AKAPs (i.e., D-AKAP2) or serine/threonine (ser/thr) kinases can compensate for the loss of D-AKAP1 function (Newhall et al., 2006) . D-AKAP1 plays a prominent neuroprotective role and is critical for mitochondrial structure/function in cell culture models. Indeed, the decreased mitochondrial localization of endogenous D-AKAP1, accomplished by treating cells with anti-AKAP1-specific peptides or by transfecting cells with D-AKAP siRNA, leads to robust mitochondrial fragmentation, increased oxidative stress, and elevated basal cell death (Affaitati et al., 2003; Livigni et al., 2006; Perrino et al., 2010; Merrill et al., 2011) . Conversely, the overexpression of D-AKAP1 blocks serum withdrawalinduced apoptosis in neuronal PC12 cells by phosphorylating the BH3 only containing proapoptotic protein BAD. Mechanistically, D-AKAP1-induced neuroprotection requires the PKA-mediated phosphorylation of BAD at serine 155, which leads to its cytosolic sequestration by 14-3-3 proteins and blocks the release of cytochrome c (Affaitati et al., 2003) . In addition to the PKA-mediated phosphorylation of BAD, mitochondrial fusion through the PKA-mediated phosphorylation of Drp1 has been recently identified as a second molecular mechanism by which D-AKAP1 confers neuroprotection. In hippocampal neurons, the transient expression of a constitutively active form of the C subunit of PKA targeted to the mitochondrion or of wild-type D-AKAP1, but not a PKA-binding-deficient mutant of D-AKAP1, fuses mitochondrial networks in the soma (Merrill, et al., 2011) and in dendrites of hippocampal neurons . Enhanced mitochondrial fusion by D-AKAP1 is associated with the enhanced resistance of hippocampal neurons to various toxic insults, including rotenone, hydrogen peroxide, and staurosporine (Merrill et al., 2011) .
As a negative feedback mechanism, D-AKAP1 recruits phosphatases to prevent excessive PKA activity at the mitochondrion that otherwise can be detrimental. For instance, in nonneuronal cells, the C subunit of PP2A interacts with D-AKAP1 in lung tissue to regulate epidermal growth factor (EGF)-mediated 90 kDa ribosomal S6 kinase 1 (RSK1) activity in fibroblasts to ensure the timely deactivation of PKAregulated mitochondrial fusion (Chaturvedi et al., 2009) . Although PP2A/Bβ2 translocates to mitochondria to dephosphorylate the same PKA-regulated site in Drp1 (Ser656) to promote mitochondrial fission (Dagda et al., 2008; Merrill et al., 2013) , it remains to be elucidated whether D-AKAP1 can spatially and simultaneously recruit endogenous PP2A in neurons as a negative feedback mechanism to halt PKA signaling. Another mechanism that regulates the level of mitochondrial PKA activity at the OMM is through the ubiquitinproteasome-mediated degradation of D-AKAP1. D-AKAP1 levels in the OMM can be rapidly degraded during hypoxic stress in neurons. D-AKAP1 is specifically tagged for ubiquitin-proteasome-mediated degradation by the E3 ubiquitin ligase seven in-absentia homolog 2 (Siah2) in neurons during hypoxic stress in vivo. Therefore, the Siah2-mediated degradation of D-AKAP1 during hypoxic conditions uncouples PKA signaling at the mitochondrion, which leads to a detrimental decrease in mitochondrial respiration in the ischemic brain (Carlucci et al., 2008) . In addition to hypoxia, future endeavors should elucidate whether oxidative stress elicited by mitochondrially directed toxins [e.g., rotenone and 6-hydroxydopamine (6-OHDA)] promote mitochondrial dysfunction by enhancing the ubiquitin-proteasome-mediated degradation of endogenous D-AKAP1 to uncouple PKA signaling in the mitochondria. D-AKAP1 can enhance the mitochondrial import of mRNAs that encode mitochondrial antioxidants and metabolic regulators of oxidative phosphorylation. For instance, the KH domains located on the C-terminal region of D-AKAP1 can directly associate with several mRNAs that encode for manganese superoxide dismutase, the F 0 -f subunit of ATP synthase, and lipoprotein lipase in HeLa cells Unal et al., 2008) . In light of these observations, future studies should address whether enhanced mitochondrial import of mRNA is an additional neuroprotective mechanism of D-AKAP1.
In addition to remodeling mitochondria through the mitochondrial fission/fusion machinery, the removal of irreversibly damaged mitochondria through autophagy, also termed mitophagy, is critical for the maintenance of high quality mitochondria in neurons. Emerging evidence suggests that PKA is a modulator of autophagy in neurons. In conjunction with PKC (Jiang et al., 2010) , PKA also phosphorylates the autophagy cargo recognition receptor microtubule-associated protein 1A/1B-light chain 3 (LC3) to suppress autophagic flux induced by rapamycin (a pharmacological activator of autophagy) or as induced by various cell culture models of PD (Cherra et al., 2010; Dagda et al., 2011) . Suggesting a role of autophagy in neurite maintenance, the suppression of autophagic flux via the PKA-mediated phosphorylation of LC3 is associated with increased neurite outgrowth in primary cortical neurons and blocks autophagy-mediated blunting of neurites induced by the overexpression of a PD-associated LRRK2 mutant (G2019S) Plowey et al., 2008) . Recent evidence suggests that D-AKAP1 is a regulator of mitochondrial turnover by maintaining mitochondrial health . Moreover, enhanced PKA signaling via D-AKAP1 overexpression suppresses autophagy induced by 6-OHDA and by loss of endogenous PTEN-induced kinase 1 (PINK1), a large mitochondrial ser/ thr kinase associated with familial recessive forms of PD .
D-AKAP1 can associate with the OMM-localized Na/ Ca 2+ exchanger NcX3 to facilitate the efflux of calcium from mitochondria as suggested by several in vitro models of ischemia (Scorziello et al., 2013) . Hence, it is plausible that D-AKAP1 preserves mitochondrial function by preventing the pathological accumulation of Ca 2+ in mitochondria by promoting Ca 2+ efflux through NcX3 located in postsynaptic and presynaptic compartments of neurons.
D-AKAP2 is a second dual specificity mitochondrially targeted AKAP that recruits PKA to the OMM (Huang et al., 1997; Wang et al., 2001) . However, unlike D-AKAP1, D-AKAP1 is unique in that it contains two RGS domains and exhibits mixed cytosolic and mitochondrial localization. Paradoxically, D-AKAP2 is not a classic RGS protein given the lack of evidence supporting an interaction of D-AKAP2 with Gα subunits. Although much is known about the 3D structure of D-AKAP2 and the molecular mechanism by which it binds with type II R subunits of PKA (Kinderman et al., 2006) , very little is known regarding the physiological function of D-AKAP2 in eukaryotic cells. In nonneuronal cells, D-AKAP2 regulates endosomal trafficking and the recycling of the transferrin receptor (Eggers et al., 2009) , which raises the possibility that D-AKAP2 regulates endosomal trafficking in neurons as well.
In peripheral neurons, immunohistochemical studies in muscle tissue showed that D-AKAP2 localizes as discrete protein clusters at the synaptic terminals of motor axons. Given that PKA is a major regulator of neurotransmitter release (Yoshihara et al., 2000) , it is conceivable that D-AKAP2 regulates the release of acetylcholine in motor neurons that innervate the skeletal muscle. Hence, future endeavors should focus on the possible interplay of D-AKAP1 and D-AKAP2 at presynaptic and postsynaptic sites for regulating different aspects of neurite biology.
Rab32 is a third mitochondrially directed AKAP that associates with type II R subunits of PKA. Rab32, a 25kDa GTPase, was identified as a regulator of mitochondrial dynamics and fusion in nonneuronal cell lines. Like D-AKAP1, Rab32 promotes mitochondrial fusion, regulates mitochondrial movement at the microtubule organizing center, and upregulates survival by phosphorylating Drp1 and BAD in HeLa cells (Alto et al., 2002) . Moreover, this small mitochondrial GTPase regulates calcium handling and translocation of calnexin at the ER (Bui et al., 2010) . However, on the basis of mRNA expression levels alone, it is likely that D-AKAP1 splice variants play a predominant role in mitochondrial dynamics compared with Rab32 given that endogenous Rab32 is almost undetectable in human brain tissue (Alto et al., 2002) .
Role of PKA in regulating dendrite morphology and function
The maintenance of complex dendritic arbors and axons depends on a proper level of neurotrophic support, continuous synaptic input, efficient anterograde movement of mitochondria, and maintenance of functional mitochondria through the continuous activation of mitochondrial quality control pathways (Reichardt, 2006; Wang et al., 2011a,b; Schwarz, 2013; Ashrafi et al., 2014) . A variety of ser/thr kinases that have been identified to regulate neurite development include extracellular-regulated kinase (ERK), PKA, Ca 2+ /calmodulin-dependent (CAM) kinase, and protein kinase C (PKC) (Goshima et al., 1993; Gomez et al., 2002; Strack, 2002; Tominaga-Yoshino et al., 2002; Dickey and Strack, 2011; Sarina et al., 2013) . PKA is a bona fide regulator of neurite biogenesis and morphology (Rodger et al., 2005; Aglah et al., 2008) . Distinct endogenous pools of PKA modulate neurite function, including dendrite outgrowth, activity of L-type Ca +2 channels in postsynaptic densities, dendritic spine morphology, dopamine biosynthesis at synaptic terminals, axonal regeneration, and remodeling (Davare et al., 1999; Dagda et al., 2011; Dickey and Strack, 2011; Merrill et al., 2011) .
In various cell culture models, PKA can indiscriminately remodel both presynaptic and postsynaptic compartments in developing neurons (Rydel and Greene, 1988; Kim and Wu, 1996; Aglah et al., 2008) . Interestingly, PKA regulates dendritic morphology in a bimodal manner. Paradoxically, although a basal amount of PKA activity is required for promoting neurite outgrowth, high levels of PKA activity simplify and shorten dendrites in neurons (Xu et al., 2012; Copf, 2014) . For instance, treating spiral ganglion neurons with a low concentration of cAMP promotes the sprouting of dendrites, whereas high concentrations of cAMP blunt dendrites and promote apoptosis even in the absence of toxic insults (Xu et al., 2012) . Therefore, a proper balance of local PKA activity is critical for promoting optimal growth of dendritic arbors in developing neurons.
Several distinct AKAPs have been identified to regulate dendrite morphogenesis. For instance, microtubuleassociated protein 2B (MAP2B), a well-characterized AKAP in neurons, forms crossbridges with microtubules required for neurite outgrowth and for stabilizing dendrite arbors in developing neurons. In vivo, MAP2B knockout mice show a severe loss of microtubule crossbridges leading to a dramatic shortening of dendrites in the cortex and hippocampus, suggesting that type II R-associated PKA pools in dendrites is essential for dendritogenesis (Harada et al., 2002) . Unexpectedly, this severe decrease in endogenous dendritic-localized PKA holoenzymes leads to a robust decrease in global PKA activity in MAP2B knockout mice, suggesting that dendritic-localized PKA is the predominant pool of PKA in neurons (Harada et al., 2002) .
A proper level of mitochondrial density at neurites is critical for the structural maintenance and proper development of postsynaptic and presynaptic compartments in neurons. Indeed, a landmark study unequivocally showed that mitochondria are critical for the development of dendritic spines, dendrites, and synapses as the expression of dominant negative mutants of the fission promoter Drp1 reduced dendrite complexity and reduced the number of synapses in neurons (Li et al., 2004) . At the postsynaptic site, mitochondria are critical for powering the mobilization and recycling of the reserve pool vesicles in Drosophila, an event downstream of PKA signaling (Verstreken et al., 2005) . In vivo, the knockdown of endogenous Drp1 depletes mitochondria from neurites and sensitizes midbrain dopaminergic neurons to degeneration (Berthet et al., 2014) . In addition, a deficiency in mitochondrial trafficking to dendrites by knocking down the dendrite-specific trafficking protein kinesinbinding (TRAK) family adaptor protein TRAK2 depletes dendrites of mitochondria and shortens dendrites (van Spronsen et al., 2013) . One study raised the possibility that mitochondrially localized PKA (PKA/D-AKAP1) is an essential regulator of dendritic development. The transient expression of D-AKAP1 increased dendritic complexity while reducing synaptic connectivity in hippocampal neurons. D-AKAP1 promotes dendritic outgrowth partly by remodeling mitochondrial morphology as the transient expression of a PKA phosphomimetic construct of Drp1 (S656D) phenocopied the enhanced dendritic complexity induced by D-AKAP1 overexpression. Mechanistically, D-AKAP1-mediated dendritogenesis involves increased mitochondrial density at dendrites and an enhanced bioenergetics status and optimal calcium buffering activity of dendritic mitochondria . A recent study showed that PINK1 plays a role in neuronal development. Indeed, the transient expression of an N-terminal truncated version of PINK1, which lacks the mitochondrial leader sequence and predominantly positions PINK1 at the cytosol, enhances the complexity of dendritic arbors and induces a modest morphological effect in axons, suggesting that cytosolic-localized PINK1 plays a neurodevelopmental role. Mitochondrially localized PKA was identified as the downstream effector of PINK1-mediated dendritic outgrowth as the transient coexpression of a mitochondrially targeted inhibitor of PKA abrogated the ability of PINK1 to enhance neurite outgrowth (Dagda et al., 2014) . Like PKA/D-AKAP1, PINK1 regulates mitochondrial function, morphology, biogenesis, and survival (reviewed in Cookson, 2005) . Collectively, these observations suggest that mitochondrial PKA and PINK1 participate in a similar prosurvival signaling pathway for regulating dendrite morphogenesis and for the maintenance of dendritic arbors.
PKA regulates cytoskeletal dynamics in vivo. In the adult nervous system, transgenic flies that express a mutant C subunit of PKA lead to a reduction in lengths and complexity of dendritic arbors, suggesting that PKA plays a critical role in regulating the basal number of dendritic branch points (Copf, 2014) . Furthermore, it is worth noting that PKA in this experimental context is involved in regulating the branching and outgrowth of dendrites without altering the polarity in dendrites as well. Although dynein was demonstrated to be phosphorylated by PKA in vitro, the transgenic expression of a PKA phosphomimetic mutant of dynein in vivo was not able to phenocopy the effects of PKA expression for elevating dendritic complexity, suggesting that the PKA-mediated phosphorylation of dynein is not sufficient for governing dendrite morphogenesis and/or that other unidentified pools of PKA are required for remodeling dendritic arbors (Copf, 2014) .
PKA dysregulation in neurode generative disorders
Alzheimer's disease PKA dysregulation in neurodegenerative disorders has been highlighted by several studies over the last 15 years. In particular, there is strong evidence showing that PKAregulated pathways in the hippocampus contribute to molecular pathogenesis and cognitive decline in AD.
For instance, a study by Tong et al. (2001) reported that levels of amyloid β 1-42, or Aβ(1-42), which do not compromise the survival of cortical neurons, interfere with functions critical for neuronal plasticity. In brief, the pretreatment of cells with Aβ(1-42), at sublethal concentrations, suppressed the activation and transcription of brain-derived neurotrophic factor (BDNF) and the phosphorylation of cAMP response element binding protein (p-CREB). Interestingly, in addition to suppressing p-CREB, another study showed that treating neurons with sublethal concentrations of Aβ(1-42) interferes with BDNFinduced activation of other prosurvival ser/thr kinases, including the extracellular signal-regulated protein kinase (ERK) and the phosphatidylinositol 3-kinase/Akt pathways (Tong et al., 2004) . Considering the critical role that CREB and BDNF play in neuronal plasticity and learning and memory, the previously mentioned observations suggest that Aβ peptides contribute to a gradual cognitive decline by suppressing PKA signaling in AD. Aβ(1-42) can also promote mitochondrial dysfunction and impair mitochondrial trafficking at the neurites of hippocampal neurons (Devi and Anandatheerthavarada, 2010) . For instance, Rui et al. (2006) showed that a brief exposure of hippocampal neurons to Aβ(1-40) results in a rapid and severe impairment of mitochondrial trafficking without inducing obvious morphological changes, which was alleviated by stimulation of PKA effectively. In addition to hippocampal neurons, Aβ(1-40) treatment caused a dysregulation of PKA-regulated signaling pathways in cortical neurons. In a recent study, Wang et al. (2011a,b) reported that persistent treatment of primary cortical neurons with Aβ(1-40) promotes the desensitization of the β 2 adrenergic receptor leading to decreased cAMP levels, reduced PKA phosphorylation of serine 845 on AMPA receptor subunit 1 (GluR1), and decreased AMPA receptormediated miniature excitatory postsynaptic currents. Paradoxically, although low amounts of intracellular Aβ drive the transcription of CREB-regulated genes, high loads of intracellular Aβ induced by the stable overexpression of an amyloid precursor protein (APP) containing AD-associated mutations result in the sustained hyperphosphorylation of CREB that fails to translocate to the nucleus (Arvanitis et al., 2007) . The failure in CREB nuclear translocation could be a key factor in early synaptic dysfunction and behavioral impairments that are exacerbated by extracellular Aβ accumulation.
Given that PKA signaling appears to be adversely affected in the Aβ(1-42) model of AD, can the pharmacological modulation of PKA and CRE-dependent transcription be considered feasible therapeutic targets for early phases of AD? Several studies have highlighted the potential of cAMP as an experimental therapy. For instance, Vitolo et al. (2002) have demonstrated in their study that the Aβ(1-42) treatment of cultured hippocampal neurons leads to a robust decline of CREB phosphorylation and of long-term potentiation (LTP), pathological events that are reversed by rolipram, a specific inhibitor of type IV phosphodiesterases. Conversely, the reversal of LTP inhibition by Rolipram and forskolin was blocked by H89, a pharmacological inhibitor of PKA (Vitolo et al., 2002) . Furthermore, treating M17 cells expressing an AD-associated mutant of APP with cAMP rescues the deficiencies in mitochondrial biogenesis, mitochondrial dysfunction, and decreased p-CREB, suggesting that a decline in mitochondrial PKA signaling is directly associated with AD pathology (Sheng et al., 2012) . Nobiletin, a naturally occurring polymethoxylated flavone from Citrus depressa that enhances PKA/CREB-dependent signaling, has been shown to reverse Aβ(1-42)-induced decreases in CREB phosphorylation in cultured hippocampal neurons (Matsuzaki et al., 2006) . In a more recent study, Wang et al. (2009) reported that the inhibition of LTP by β-amyloid is prevented by the activation of β2-adrenoceptors and by the pharmacological activation of the cAMP/PKA signaling pathway in rat hippocampal slices. Collectively, these aforementioned observations suggest that Aβ can directly and indirectly negatively impact PKA-regulated signaling pathways, whereas pharmacological agents that enhance the cAMP/PKA/CREB-signaling pathway have the potential for the treatment of AD.
Huntington's disease
Several studies have reported mitochondrial abnormalities to be involved in Huntington's disease (HD) progression. However, the evidence for dysregulated PKA signaling is sparse and not very clear in different HD models. For instance, Giralt et al. (2011) observed hippocampal PKA hyperactivation in naive R6/1 mice (mutant huntingtin transgenic mice) compared with wild-type mice. In conjunction with the overactivation of the PKA signaling pathways, the authors observed a significant downregulation of protein expression levels of phosphodiesterase 4. Likewise, hippocampal PKA inhibition by infusion of Rp-cAMPS, a reversible PKA inhibitor, restored long-term memory in R6/2 mice, suggesting that the overactivation of global PKA signaling in the hippocampus is one of the molecular mechanisms underlying cognitive decline in R6 animals. Furthermore, a recent study by Lin et al. (2013) demonstrated that lower PKA activity was associated with proteasome impairment in the synaptic fractions from the striatum of two HD mouse models (R6/2 and N171-82Q) and in mutant HTT (mHTT)-expressing striatal cells. Interestingly, in this study, the pharmacological activation of PKA enhanced the phosphorylation of Rpt6 (a component of the proteasome), rescued the impaired proteasome activity, and reduced mHTT aggregates. Overall, these published observations suggest that the bimodal dysregulation of PKA signaling contributes to cognitive decline and memory impairment in the hippocampus in the case of overactive PKA signaling and decreased PKA signaling contributes to the degeneration of medium spiny neurons. Therefore, new therapeutic interventions should be developed and tailored for 'normalizing' PKA signaling in hippocampal and striatal neurons to reverse cognitive decline while preventing neurodegeneration.
Parkinson's disease
The evidence for a dysregulation of PKA signaling pathways in PD has been observed in in vivo and in vitro models as well as in postmortem PD brain tissue. Indeed, Howells et al. (2000) were among the first to report a dysregulation of PKA-regulated genes when the authors of this study showed that mRNA levels of BDNF were significantly reduced in substantia nigra neurons before degeneration.
Given that mitochondrial dysfunction and fragmentation contributes to neurodegeneration in various in vitro and in vivo PD models, it is plausible that a decline in mitochondrial-derived PKA signaling contributes to PD etiology. Indeed, the decreased PKA-mediated phosphorylation of the mitochondrial fission inducer Drp1 has been observed in cell culture models of PD. In a genetic cell culture model of PD, the RNAi-mediated knockdown of endogenous PINK1 led to the decreased PKA-mediated phosphorylation of Drp1 and a concomitant increase in calcineurin (PP2B)-mediated Drp1-dependent mitochondrial fission (Sandebring et al., 2009) . Moreover, the transient expression of D-AKAP1 or phosphomimetic mutants of Drp1 prevents cell death induced by PINK1 loss, suggesting that the loss of the PKA-mediated phosphorylation of Drp1 through D-AKAP1 contributes to cellular pathology associated in PINK1-deficient cells . Recently, Parisiadou et al. (2014) demonstrated that LRRK2, a large ser/thr kinase that is mutated in an autosomal dominant familial form of PD characterized by cortical Lewy body pathology (Poulopoulos et al., 2012) , is a new atypical AKAP-like regulator of PKARIIβ in dendrites of neurons. The PD-associated LRRK2 R1441C missense mutation impaired the interaction of LRRK2 with PKARIIβ and induced excessive PKA activity in the dendritic spines of these neurons, which compromised their sensitivity to stimulation via dopamine receptor D1 (Parisiadou et al., 2014) . Furthermore, Chalovich and colleagues showed that the 6-OHDA treatment of B65 neuronal cells led to an aberrant mislocalization of pCREB from the nucleus to the cytosol and decreased total PKA signaling, which was accompanied by decreased mRNA levels of BDNF and Bcl-2, two PKA-regulated genes. Conversely, cAMP treatment reversed 6-OHDA-induced cell death and restored nuclear localization of p-CREB. There is credence for the concept that the mislocalization of p-CREB contributes to PD etiology (Chalovich et al., 2006) . An aberrant accumulation of p-CREB granules has been reported in the cytoplasm of substantia nigra dopaminergic neurons in postmortem PD brain tissue compared with age-matched control cases, suggesting that the decreased PKA-mediated transcription of prosurvival genes is hampered because of the cytosolic sequestration of p-CREB (Chalovich et al., 2006) . In further support of this concept, the dysregulation of CREB has been observed in other tissue culture models of PD. Recently, Dagda et al. (2014) reported decreased global PKA activity in stable PINK1 knockdown cells, which was correlated with decreased nuclear p-CREB. Recent studies have shown proof of concept that pharmacological activators of PKA may pose as a promising therapeutic intervention for ameliorating mitochondrial dysfunction in familial PD. For instance, Dagda et al. (2011) demonstrated that the treatment of PINK1-deficient SH-SY5Y cells with pharmacological PKA activators or the transient expression of a constitutively active form of mitochondrially targeted PKA or D-AKAP1 reversed mitochondrial fragmentation. In a recent study, Hwang et al. (2014) reported that the mitochondrial membrane transport protein human uncoupling protein 2 (hUCP2) protected dopamine neurons in adult flies against rotenone-mediated mitochondrial fragmentation and toxicity by increasing intracellular cAMP levels. By contrast, PKA inhibitors blocked the preserved mitochondrial integrity, movement, and cell survival induced by hUCP2 in hUCP2-expressing dopamine neurons exposed to rotenone. The neuroprotective role of PKA in PD is further highlighted by the study by Yang et al. (2008) , which showed attenuation of MPTP toxicity by rolipram. Hence, this study shows proof of concept that phosphodiesterase inhibitors are promising anti-PD therapeutic agents that can delay the degeneration of substantia nigra dopaminergic neurons.
Conclusion
In summary, PKA signaling -as regulated by AKAPsgoverns mitochondrial morphology, function, mitochondrial trafficking, and neuronal survival during physiological conditions. However, during conditions of enhanced oxidative stress, dysregulated PKA signaling in various neuronal subcompartments of specific neuronal populations contributes to a converging molecular pathology in a spectrum of brain degenerative diseases, including mitochondrial dysfunction, increased ROS, impaired mitochondrial trafficking, and unopposed apoptotic signaling (Figure 1) . Hence, understanding how PKA is dysregulated in various neuronal subcompartments will help guide the development of future pharmacological therapies for reversing degeneration in various brain degenerative diseases.
It is worth noting that the use of mitochondrially directed antioxidants, calcium chelators/metal proteinbinding compounds, N-methyl D-aspartate receptor inhibitors, and caspase inhibitors has been developed but has demonstrated modest to no benefit in clinical trials for treating various brain degenerative disorders (Snow et al., 2010; Johansson et al., 2011; Bonelli and Wenning, 2006; Regland et al., 2001; Sampson et al., 2012) . The development of pharmacologically active compounds that can tout protective signaling in neurons poses a paramount challenge because of the compartmentalized nature of PKA signaling pathways in neurons.
Although the use of global pharmacological activators of PKA (cAMP and rolipram) to reverse the loss of neurites as induced by brain degenerative disorders is tractable, serious side effects associated with high doses of global PKA activators include epilepsy and loss of dendrites (Ludvig et al., 1992; Xu et al., 2012) . Hence, it is imperative that pharmacological or viral-mediated gene therapy be developed and experimentally tested preclinically for future use in humans to reverse neurodegeneration in PD and AD. A continuous level of mitochondrial turnover, anterograde trafficking of mitochondria to neurites (shown for dendrites only), neurotrophic support as maintained by protective ser/thr kinases (PINK1 and PKA), and dendrite-remodeling events are required to maintain dendritic arbors and synaptic connectivity in neurons under physiological conditions (top half of the figure). However, loss of protective PKA signaling as induced by oxidative stress and as evidenced in PD and AD models leads to increased oxidative stress, Drp1-dependent mitochondrial fragmentation, decreased oxidative phosphorylation, impaired mitochondrial trafficking, decreased mitochondrial biogenesis, and altered CREB localization/transcriptional-related activities (bottom half of the figure). Future endeavors should focus on developing therapies with the end goal of 'normalizing' the activities of distinct compartmentalized pools of PKA in neuronal subpopulations affected by brain degenerative diseases. Key: yellow bolts -reactive oxygen species/toxic insult; orange lines in dendrites -microtubules; green arrow in nucleus -transcriptional activity.
